1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with bb 1101 in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (bb 1101) | Trials (bb 1101) | Recent Studies (post-2010) (bb 1101) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 22 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gearing, A; Gendelman, HE; Limoges, J; Persidsky, Y; Rasmussen, J; Zheng, J | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and bb 1101
| Article | Year |
|---|---|
Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis.
Topics: AIDS Dementia Complex; Animals; Benzyl Compounds; Cell Survival; Dexamethasone; Disease Models, Animal; Drug Combinations; Gliosis; HIV-1; Humans; In Vitro Techniques; Interleukin-1; Interleukin-8; Leucine; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, SCID; Microglia; Neurons; Pentoxifylline; Platelet Activating Factor; Protease Inhibitors; Succinates; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2001 |